<DOC>
	<DOCNO>NCT01987752</DOCNO>
	<brief_summary>This study Post-Marketing Surveillance study Korea evaluate safety efficacy Combigan® ( brimonidine tartrate/timolol maleate ) Ophthalmic Solution patient Open Angle Glaucoma Ocular hypertension insufficient response local beta blocker treat per standard care clinical practice .</brief_summary>
	<brief_title>Safety Efficacy Combigan® Ophthalmic Solution Korea</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate , Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients Open Angle Glaucoma Ocular Hypertension treat Combigan® Ophthalmic Solution standard care clinical practice .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>